Patents Assigned to Merck Frosst Canada
  • Gamma-ketoacid dipeptides as inhibitors of caspase-3
    Patent number: 6525025
    Abstract: This invention encompasses the novel compounds of Formula I, which are useful in the treatment of caspase-3 mediated diseases. The invention also encompasses certain pharmaceutical compositions comprising compounds of Formula I as well as methods for treatment of caspase-3 mediated diseases.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: February 25, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Erich L. Grimm, Renee Aspiotis, Cameron Black
  • High level expression of human cyclooxygenase-2
    Publication number: 20030032789
    Abstract: The invention discloses a cDNA consisting of human cyclooxygenase-2 cDNA attached to 3′ flanking sequence of human cyclooxygenase-1 methods for increasing the expression of human cyclooxygenase-2 in transformed cells and assays for preferentially and independently measuring cyclogenase-2 in samples.
    Type: Application
    Filed: October 25, 2001
    Publication date: February 13, 2003
    Applicant: Merck Frosst Canada & Co.
    Inventors: Gary P. O'Neill, Joseph A. Mancini
  • Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
    Patent number: 6498151
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: December 24, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
  • Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Patent number: 6486141
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related conditions.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Cheuk Kun Lau, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Chun Sing Li, Patrick Roy, Michel Therien, Zhaoyin Wang
  • Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Patent number: 6486142
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and conditions related to diabetes.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michel Therien, John Scheigetz, Zhaoyin Wang
  • Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
    Patent number: 6486194
    Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Publication number: 20020173661
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 20, 2002
    Publication date: November 21, 2002
    Applicant: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
    Patent number: 6465444
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: October 15, 2002
    Assignees: Merck Frosst Canada & Co., Banyu Pharmaceutical Co., Ltd.
    Inventors: Christopher Bayly, Mitsuru Ohkubo
  • Pyrones as inhibitors of cyclooxygenase-2
    Patent number: 6465509
    Abstract: The invention encompasses the novel compounds of Formula I, which are useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions comprising compounds of Formula I as well as methods of treating cyclooxygenase-2 mediated diseases comprising administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Formula I.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: October 15, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun-Sing Li, Cheuk Kun Lau, Michel Therien, Petpiboon Prasit
  • Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor
    Patent number: 6448274
    Abstract: A PDE4 inhibiting compound is represented by
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: September 10, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Friesen, Yves Ducharme, Yves Girard, Chun Li, Annette Robichoud
  • Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
    Patent number: 6448429
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: September 10, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Robert Young
  • Pyrazinones, compositions containing such compounds and methods of use
    Patent number: 6444811
    Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts, esters, N-oxides and hydrates thereof are disclosed. Pharmaceutical compositions and methods of use are also included. The compounds are active against the caspase-3 enzyme, and thus are useful to treat fin caspase-3 mediated diseases and conditions.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: September 3, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Robert Zamboni, Daniel J. McKay, Christopher I. Bayly, Erich L. Grimm, John Colucci
  • Methods of identifying modulators of prostaglandin receptor EP1
    Patent number: 6440680
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: August 27, 2002
    Assignees: Merck Frosst Canada, Inc., Vanderbuilt University
    Inventors: Anthony Ford-Hutchinson, Colin Funk, Richard Grygorczyk, Kathleen Metters
  • Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6'- methyl-[2,3']bipyridinyl
    Patent number: 6441002
    Abstract: Polymorphic, amorphous and hydrated forms of the title compound having the following structure: are disclosed. The compound is a potent and selective cyclooxygenase-2 (COX-2) inhibitor.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 27, 2002
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Sophie Dorothee Clas, Louis S. Crocker, James A. McCauley, Ian Davies, Chad Dalton
  • PDE IV inhibiting amides, compositions and methods of treatment
    Patent number: 6436965
    Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts and hydrates thereof are disclosed as useful for treating or preventing diseases and conditions mediated by PDE-IV. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: August 20, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Marc Labelle, Claudio Sturino, Nicolas Lachance, Dwight Macdonald
  • Process for making 2, 5-substituted pyridine
    Patent number: 6420565
    Abstract: 2-lithio-5-halopyridine is formed as a predominant component of a reaction mixture by reacting BuLi with 2,5-dihalopyridine in a non-coordinating solvent.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: July 16, 2002
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co
    Inventors: Paul O'Shea, Xin Wang, Richard Tillyer
  • Methods for inhibiting bone resorption
    Patent number: 6414006
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: July 2, 2002
    Assignees: Merck Frosst Canada & Co., Merck & Co., Inc.
    Inventors: Shun-ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc LaBelle, Kathleen Metters, Robert N. Young
  • Cyclopentanoindoles, compositions containing such compounds and methods of treatment
    Patent number: 6410583
    Abstract: Substituted cyclopentanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: June 25, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Marc Labelle, Claudio Sturino, Bruno Roy, Carl Berthelette, Michael Boyd, Nicolas Lachance, John Scheigetz
  • Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
    Patent number: 6410563
    Abstract: Novel substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: June 25, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Denis Deschenes, Daniel Dube, Michel Gallant, Yves Girard, Patrick Lacombe, Dwight MacDonald, Anthony Mastracchio, Helene Perrier
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Patent number: 6399636
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 4, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte